Background

Small fiber neuropathy (SFN) affects 40–60% of primary Sjögren syndrome (pSS) patients, often preceding sicca symptoms and evading detection by conventional nerve conduction studies. Current diagnosis relies on skin punch biopsy (intraepidermal nerve fiber density, IENFD) — an invasive, non-repeatable procedure ill-suited for longitudinal monitoring. Corneal confocal microscopy (CCM) quantifies sub-basal corneal nerve fiber density (CNFD), branch density (CNBD), and fiber length (CNFL) non-invasively in minutes, and the cornea shares trigeminal innervation patterns homologous to peripheral small fibers.

Hypothesis

Serial CCM-derived CNFD decline rate (ΔCNFD/month), when combined with tear film inflammatory cytokine ratios (IL-6/IL-10, CXCL10/CXCL12), predicts systemic SFN progression — defined as ≥20% worsening in quantitative sensory testing (QST) thermal thresholds — 6–12 months before QST deterioration becomes clinically detectable in pSS patients.

Mechanistic Rationale

Corneal nerves undergo Wallerian-like degeneration driven by the same dorsal root ganglion (DRG) T-cell infiltration and anti-neuronal antibody-mediated damage that causes systemic SFN in pSS. The cornea, being the most densely innervated tissue in the body (~7,000 nociceptors/mm²), amplifies early neurodegenerative signals before they manifest in less densely innervated dermatomes. Tear film cytokine shifts from reparative (IL-10, CXCL12) to pro-inflammatory (IL-6, CXCL10) profiles reflect local neuroinflammatory escalation that parallels systemic DRG inflammation.

Testable Predictions

1. Primary: pSS patients with ΔCNFD < −0.8 fibers/mm/month over 3 consecutive visits will develop ≥20% QST thermal threshold worsening within 12 months (HR >3.0, 95% CI excluding 1.0)
2. Secondary: Adding tear IL-6/IL-10 ratio >2.5 to the CNFD slope model improves C-statistic from ~0.72 (CNFD alone) to >0.82
3. Negative control: CNFD decline rate will NOT predict large fiber neuropathy (NCS-confirmed) progression, confirming specificity for small fiber pathology
4. Dose-response: Patients in the fastest CNFD decline tertile will have 3× higher risk of developing autonomic SFN symptoms (orthostatic intolerance, gastroparesis) versus the slowest tertile

Proposed Study Design

Prospective cohort, n=150 pSS (ACR/EULAR 2016 criteria), quarterly CCM + tear cytokine panels + semiannual QST + annual skin biopsy (IENFD as gold standard). 24-month follow-up. Time-dependent Cox regression with CNFD slope as continuous time-varying covariate. Bonferroni correction for 4 co-primary/secondary endpoints (α=0.0125).

Limitations

• CCM requires specialized ophthalmic equipment (Heidelberg Retina Tomograph III), limiting multicenter feasibility
• Tear cytokine panels lack standardization across laboratories
• Concomitant dry eye disease may cause corneal nerve changes independent of systemic SFN
• QST is operator-dependent and subject to patient cooperation bias
• 150 patients may be underpowered for subgroup analyses (autonomic SFN)
• Cannot distinguish anti-neuronal antibody-mediated from ischemic SFN mechanisms

Clinical Significance

If validated, serial CCM would replace invasive skin biopsies for SFN monitoring in pSS, enabling non-invasive, repeatable tracking at routine ophthalmology visits. Early detection of SFN progression 6–12 months before clinical worsening opens a therapeutic window for neuroprotective interventions (IVIG, rituximab) before irreversible axonal loss. The combined CCM + tear cytokine model could be integrated into existing ESSDAI frameworks as a quantitative neurological domain score.

LES AI • DeSci Rheumatology